As Amgen gears up to launch osteoporosis candidate denosumab, a host of smaller players are working on what they see as the next-generation therapies: those that help build up new bone. Tough economic times across the board, plus the high development risks and costs associated with osteoporosis--a chronic, primary care condition--are making financing almost impossible for some.
By Melanie Senior
In a sense, it’s easy to see why most companies would want to steer away from trying to develop a...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
Lynkuet will compete with Astellas's Veozah/Veoza
CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.
Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.
